WB: Use at a dilution of 1/200 - 1/250. Detects a band of approximately 105 kDa. Optimal dilutions/concentrations should be determined by the end user.
Rat cortical membranes
This antibody does not cross-react with other members of the PDE4D family or with other PDE4 proteins (PDE4A, B and C) or with other PDE family members.
Preservative: 0.02% Sodium Azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.8 mg/ml (Please refer to the vial label for the specific concentration.)
Synthetic peptide (unfortunately, the amino acid sequence is considered to be commercially sensitive) (N terminal).
Immunogen affinity purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Cyclic AMP-dependent Phosphodiesterase 4 type D (PDE4D) family includes 5 variants (PDE4D1, D2, D3, D4 and D5). One or more PDE4D subtype-variants are ubiquitously present in all mammalian cells. In CNS all five PDE4D subtype-variants are expressed in varying ratios and their activity is regulated in tandem with GPCRs stimulation and selective phosphorylation by PKA and other kinases. Peripheral tissues also exhibit differential expression of PDE4D variants. PDE4D1/D2 mRNA levels rise in response to an increase in cAMP. Short-term regulation of PDE4D variants involved PKA, MAP kinases and Erk2 phosphorylation that results in rapid change in their enzymatic activities. Other regulatory mechanisms involved protein-protein interactions with cytoskeletal scaffolding proteins.